You have 9 free searches left this month | to do more

acalabrutinib

Acalabrutinib is a drug used to treat Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Acalabrutinib is being actively studied in 66 studies and prior, has been studied in 13.

Top SponsorsTop SitesTop Investigators
Acerta Pharma BVResearch SiteAustin I Kim
AstraZenecaM D Anderson Cancer CenterCarsten Utoft Niemann
M.D. Anderson Cancer CenterBeth Israel Deaconess Medical CenterCraig Moskowitz
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
2021-08-04
Aug 4, 2021
U
Recruiting
  • Lymphoma
  • Chapel Hill, North Carolina
  • +1 more
2021-11-12
Nov 12, 2021
S
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Seattle, Washington
    Swedish Cancer Institute
2021-03-01
Mar 1, 2021
W
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • CLL/SLL
  • Acalabrutinib
  • New York, New York
    Weill Cornell Medicine
2021-11-20
Nov 20, 2021
D
Not yet recruiting
  • Central Nervous System Lymphoma
  • +2 more
  • Acalabrutinib
  • Boston, Massachusetts
  • +1 more
2021-06-07
Jun 7, 2021
U
Recruiting
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • R-CHOP chemotherapy
  • Vancouver, British Columbia, Canada
  • +2 more
2021-06-21
Jun 21, 2021
F
Recruiting
  • Recurrent Moderate-Severe Chronic Graft Versus Host Disease
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Acalabrutinib
  • Questionnaire Administration
  • Tampa, Florida
  • +3 more
2021-12-22
Dec 22, 2021
A
Completed
  • Hepatic Impairment
  • +2 more
  • acalabrutinib
  • Miami, Florida
  • +2 more
2021-08-16
Aug 16, 2021
M
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib
  • Obinutuzumab
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-18
Nov 18, 2021
M
Recruiting
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • Houston, Texas
    M D Anderson Cancer Center
2020-12-04
Dec 4, 2020
C
Recruiting
  • Autoimmune Hemolytic Anemia
  • +3 more
  • Acalabrutinib
  • Duarte, California
    City of Hope Medical Center
2021-08-10
Aug 10, 2021
F
Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-12-23
Dec 23, 2021
S
Recruiting
  • Waldenstrom Macroglobulinemia
  • Acalabrutinib
  • +2 more
  • Vancouver, British Columbia, Canada
  • +3 more
2021-07-23
Jul 23, 2021
J
Recruiting
  • Food Allergy
  • Food Allergy Peanut
  • Acalabrutinib
  • Baltimore, Maryland
    Johns Hopkins Bayview Medical Center
2021-12-30
Dec 30, 2021
W
Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-05-12
May 12, 2021
M
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib
  • +4 more
  • Scottsdale, Arizona
  • +2 more
2021-08-19
Aug 19, 2021
N
Recruiting
  • Non-Hodgkin's Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-12-30
Dec 30, 2021
N
Recruiting
  • Recurrent Follicular Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-12-16
Dec 16, 2021
M
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-08-09
Aug 9, 2021
S
Recruiting
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • Denver, Colorado
  • +3 more
2021-05-20
May 20, 2021
W
Active, not recruiting
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-01-30
Jan 30, 2021
U
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Rochester, New York
    University of Rochester
2021-02-02
Feb 2, 2021